Transcatheter Pulmonary Valve Market: as Medtronic’s Harmony valve and Edwards’ Alterra prestent system extended transcatheter pulmonary valve replacement beyond surgically modified conduits into the native, often patulous right ventricular outflow tract, congenital heart disease patients who previously had no transcatheter option beyond open-heart surgery now have a minimally invasive pathway, so the addressable transcatheter pulmonary valve patient population has expanded meaningfully beyond its original conduit-and-bioprosthetic-valve base, and long-term outcome data now accumulating from these native-anatomy devices is what will determine how completely this expanded population continues shifting away from surgical referral.

The global transcatheter pulmonary valve market size was USD 274.6 Million in 2025 and is expected to register a revenue CAGR of 11.8% during the forecast period. Market revenue growth is driven by factors such as native right ventricular outflow tract-compatible valve and prestent technology extending transcatheter treatment to congenital heart disease patients previously limited to open-heart surgery, accumulating long-term clinical outcome data supporting continued transcatheter referral over surgical alternatives, and continued growth in adult congenital heart disease patient populations requiring pulmonary valve intervention as this population ages into adulthood. The first driving factor is native right ventricular outflow tract-compatible valve and prestent technology, extending transcatheter pulmonary valve replacement to congenital heart disease patients whose surgically modified RVOT anatomy previously fell outside the sizing range of earlier transcatheter valve generations. The diameters of the surgically modified right ventricular outflow tract in many adolescents and adults with congenital heart disease are too large for the maximal diameters of first-generation transcatheter pulmonary valves, and self-expanding valve and prestent technology specifically developed for this native, often patulous anatomy directly addresses this size limitation. The second driving factor is accumulating long-term clinical outcome data from native-RVOT-compatible transcatheter pulmonary valve technology, supporting continued physician and patient confidence in transcatheter referral over surgical alternatives as this evidence base matures. Five-year follow-up data for native RVOT-compatible transcatheter pulmonary valve technology has demonstrated durable freedom from surgical intervention, freedom from catheter-based reintervention, and low mortality, providing the clinical evidence base referring physicians rely on when recommending transcatheter over surgical pulmonary valve replacement. The third driving factor is continued growth in the adult congenital heart disease patient population, as improved paediatric congenital heart surgery survival rates mean a growing population of congenital heart disease patients now reaches adulthood requiring pulmonary valve intervention. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way extending transcatheter pulmonary valve technology to native RVOT anatomy widens the addressable patient population beyond the original conduit-and-bioprosthetic-valve base without requiring an entirely new clinical referral pathway, letting the same interventional cardiology infrastructure and physician relationships built around conduit-based transcatheter pulmonary valve replacement extend naturally to this newly addressable native-anatomy population. Once an adult congenital cardiology programme has established the interventional cardiology infrastructure and referral relationships needed to perform conduit-based transcatheter pulmonary valve replacement, extending that same programme to serve native RVOT anatomy patients using self-expanding valve and prestent technology requires incremental procedural training rather than building an entirely new clinical programme and referral network from scratch, so established conduit-based transcatheter infrastructure and native-anatomy market expansion are directly linked. As a result, demand and revenue share are concentrating around manufacturers offering native RVOT-compatible technology alongside their established conduit-based transcatheter pulmonary valve portfolios, and the forecast tilts toward this combined, broader-anatomy-coverage portfolio capturing a larger share of category value growth rather than growth remaining confined to the original conduit-and-bioprosthetic-valve patient population. For instance, self-expanding transcatheter pulmonary valve technology developed specifically for native, often patulous right ventricular outflow tract anatomy has demonstrated five-year outcome data showing durable freedom from both surgical and catheter-based reintervention, illustrating how the clinical evidence base supporting native-anatomy transcatheter pulmonary valve replacement has matured sufficiently to sustain continued referral pathway conversion from surgical to transcatheter treatment for this expanded patient population. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the extension of transcatheter pulmonary valve technology to native right ventricular outflow tract anatomy, addressing a patient population that first-generation, conduit-focused transcatheter valve technology could not serve. The surgically modified right ventricular outflow tract in many adolescents and adults with congenital heart disease is frequently too large and irregularly shaped, often described as patulous, for the maximal diameters that first-generation transcatheter pulmonary valve technology was designed to fit, and self-expanding valve and prestent technology specifically engineered for this wider, irregular native anatomy directly addresses this size and shape limitation. Self-expanding transcatheter pulmonary valve and prestent technology has been developed specifically for treatment of the dysfunctional native right ventricular outflow tract, extending transcatheter pulmonary valve replacement routinely to patients with native and surgically patched RVOT anatomy who previously had no transcatheter treatment option. The effect on the market is that the addressable transcatheter pulmonary valve patient population has expanded meaningfully beyond its original conduit-and-bioprosthetic-valve base to include native RVOT anatomy patients. These are some of the key factors driving revenue growth of the market.

The second driver is the maturing clinical evidence base for native RVOT-compatible transcatheter pulmonary valve technology, which directly informs referring physicians’ confidence in recommending transcatheter treatment over open-heart surgical alternatives. A referring cardiologist recommending transcatheter over surgical pulmonary valve replacement for a congenital heart disease patient needs durable, multi-year outcome data demonstrating the transcatheter approach’s safety and effectiveness relative to established surgical outcomes, and as this longitudinal evidence base accumulates for native-anatomy transcatheter technology specifically, it directly supports sustained referral pathway conversion toward the transcatheter approach. Five-year follow-up data for native RVOT-compatible transcatheter pulmonary valve technology has demonstrated approximately 90% freedom from surgical intervention, approximately 85% freedom from catheter-based reintervention, and approximately 95% freedom from mortality, with mild or lesser regurgitation in all patients at five years. The effect on the market is that this maturing five-year outcome evidence base is directly supporting sustained physician confidence in native-anatomy transcatheter pulmonary valve referral over surgical alternatives. These are some of the key factors driving revenue growth of the market.

“Five-year follow-up data for native right ventricular outflow tract-compatible transcatheter pulmonary valve technology has demonstrated approximately 90% freedom from surgical intervention and approximately 95% freedom from mortality, providing the durable clinical evidence base that continues supporting physician confidence in transcatheter referral over open-heart surgical alternatives for this expanded congenital heart disease patient population.”

The third driver is the sustained growth in the adult congenital heart disease patient population, a direct consequence of improved paediatric congenital heart surgery survival rates over recent decades. Improved paediatric congenital heart surgery outcomes mean a growing share of children born with congenital heart disease now survive into adulthood, and many of these adult congenital heart disease patients eventually require pulmonary valve intervention as their initial paediatric surgical repair reaches the end of its functional lifespan, so improved paediatric survival and rising adult congenital heart disease pulmonary valve intervention demand are directly and sequentially linked. The adult congenital heart disease patient population continues to grow globally as paediatric congenital heart surgery survival rates improve, expanding the pool of adult patients eventually requiring pulmonary valve intervention. The effect on the market is that transcatheter pulmonary valve demand growth increasingly reflects this structural, demographic expansion of the adult congenital heart disease population, not solely improving transcatheter technology capability alone. These are some of the key factors driving revenue growth of the market.

However, the transcatheter pulmonary valve market faces severe adoption constraints from complex pre-procedural imaging and anatomical assessment requirements limiting which centres can safely perform native-anatomy transcatheter pulmonary valve replacement, device-specific manufacturing and quality considerations that have periodically affected specific product availability, and electrophysiology interaction risk requiring ongoing clinical monitoring as this patient population ages. Because native RVOT-compatible transcatheter pulmonary valve technology requires detailed gated computed tomography imaging to assess anatomical feasibility before a procedure can proceed safely, adult congenital cardiology programmes without this specific imaging and anatomical assessment expertise face a genuine access barrier to offering native-anatomy transcatheter pulmonary valve replacement, concentrating this specific technology’s availability among the largest, most specialised adult congenital cardiology programmes. Device-specific manufacturing and quality considerations are a second constraint, since the specialised, self-expanding valve and prestent technology this category depends on for native anatomy coverage requires precise manufacturing tolerances, and manufacturing process changes at any given manufacturer can periodically affect specific product availability during quality review periods, as has occurred previously in this category following changes to delivery system manufacturing processes. Electrophysiology interaction risk is the third constraint, since self-expanding valve and prestent technology interacting with the muscular right ventricular outflow tract can complicate future ventricular tachycardia ablation procedures by covering the critical anatomical isthmus these ablation procedures target, requiring ongoing clinical monitoring for sustained ventricular tachycardia risk as this treated patient population ages and the clinical community continues characterising this interaction over a longer time horizon. These factors substantially limit transcatheter pulmonary valve market growth over the forecast period.

Based on technology, the global transcatheter pulmonary valve market is segmented into self-expanding valve/prestent systems and balloon-expandable valve systems. Self-expanding valve/prestent systems hold the largest revenue share, because they address the larger, native RVOT anatomy patient population that balloon-expandable technology alone cannot serve, which suits Medtronic’s Harmony and Edwards’ Alterra platforms specifically. Balloon-expandable valve systems are expected to register a significantly large revenue share in the global transcatheter pulmonary valve market over the forecast period, reflecting their continued, well-established role in treating failed surgical conduits and bioprosthetic valves.

Congenital heart disease (native RVOT) application is expected to account for the fastest-growing revenue share in the global transcatheter pulmonary valve market during the forecast period

Based on application, the global transcatheter pulmonary valve market is segmented into congenital heart disease (native RVOT) and failed surgical conduit/bioprosthetic valve applications. Failed surgical conduit/bioprosthetic valve holds a significant revenue share, reflecting this application’s position as the original, most established transcatheter pulmonary valve treatment indication. Congenital heart disease (native RVOT) is expected to register the fastest revenue growth rate in the global transcatheter pulmonary valve market over the forecast period, driven directly by native-anatomy-compatible technology extending treatment to this previously underserved patient population, which is why this application represents the clearest growth vector within the broader market.

Native/patched RVOT anatomy is expected to account for a significantly large revenue share in the global transcatheter pulmonary valve market during the forecast period

Based on anatomy, the global transcatheter pulmonary valve market is segmented into native/patched RVOT and surgical conduit/bioprosthetic valve anatomy. Native/patched RVOT anatomy holds a significant and growing revenue share, directly reflecting the expanded patient population that self-expanding valve and prestent technology has made addressable. Surgical conduit/bioprosthetic valve anatomy remains an established revenue category, reflecting the original, longest-validated transcatheter pulmonary valve treatment indication that balloon-expandable technology continues to serve.

Based on regional analysis, the transcatheter pulmonary valve market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of adult congenital cardiology programmes globally, and because Medtronic and Edwards Lifesciences both concentrate significant commercial and clinical development activity in the country. United States and Canada clinical experience with native RVOT-compatible transcatheter pulmonary valve technology exceeds 500 implants, reflecting the scale of clinical adoption concentrated in North America specifically. The concentration of leading transcatheter pulmonary valve manufacturers and adult congenital cardiology programme expertise in the United States also means new native-anatomy-compatible technology is typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national transcatheter pulmonary valve markets within Europe. The region’s established adult congenital cardiology infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature congenital cardiology infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national transcatheter pulmonary valve markets within the region. Expanding adult congenital cardiology programme investment and rising diagnosis rates for adult congenital heart disease in China and Japan are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national transcatheter pulmonary valve markets within the region. Academic adult congenital cardiology programmes in both countries are gradually adopting native-anatomy-compatible transcatheter pulmonary valve technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised transcatheter valve systems that Latin American congenital cardiology programmes depend on through 2026, slowing adoption beyond the region’s main academic centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial transcatheter pulmonary valve markets within the GCC. The UAE is the most established transcatheter pulmonary valve market on the continent given its concentrated private hospital congenital cardiology infrastructure, while the wider Gulf states and broader African markets are still building the specialist adult congenital cardiology capacity that transcatheter pulmonary valve adoption depends on.